Lilly’s lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels Investors | Eli Lilly and Company
Serwis informacyjny, platforma współpracy grupowej, szkolenia i egzaminy
Lilly’s lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels Investors | Eli Lilly and Company
